22nd November 2024 Hyderabad, Telangana, India Monitra Healthcare Private Limited, a pioneer in health monitoring technologies, proudly announces the grant of its U.S. Patent No. 12,109,029 B2, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals. This patent, issued by the United States Patent and Trademark Office on October 8, 2024, marks a significant milestone in Monitra Health’s mission to revolutionize cardiac care through innovation.
The patented technology introduces a wireless patch-based cardiac monitoring device designed to enhance patient compliance and diagnostic accuracy. Unlike current products, the patch automatically detects its orientation on the patient and optimally selects electrode pairs to ensure the highest quality signal transmission, eliminating errors from improper placement. The device processes bio-potential signals in real-time and wirelessly transmits physiological data to external systems for further analysis.
The innovation features advanced orientation detection to reliably identify and adapt to the patch’s placement on the patient. Its dynamic electrode pairing optimizes performance by automatically selecting the most effective electrode pairs based on real-time orientation and signal quality. Seamless wireless connectivity enables efficient transmission of ECG and other physiological data to external devices for immediate processing and analysis. Additionally, the device’s lightweight, wire-free design ensures superior patient comfort, making it ideal for prolonged use.
Ravi Bhogu, Inventor and Founder of Monitra Health, stated, “This patent underlines our commitment to delivering cutting-edge technology that empowers clinicians with more reliable and actionable cardiac data. By addressing these critical needs, this innovation represents a leap forward in cardiac monitoring.By addressing key challenges such as patient compliance and signal fidelity, this innovation represents a leap forward in cardiac monitoring.”
“Monitra Health’s innovation in cardiac monitoring aligns perfectly with our vision of supporting transformative solutions with global impact out of India. This patent highlights the company’s leadership in addressing critical unmet needs in cardiovascular diagnostics,” said Rajesh Sehgal, Managing Partner, Equanimity VC.
“The grant of this U.S. patent is a testament to Monitra Health’s technological ingenuity and commitment to global excellence. We are pleased to support the company as it scales this innovation to reach patients and clinicians worldwide,” said Dhiraj Rajendran, Partner, Kotak Alternate Asset Managers.
Monitra Health’s patented technology promises to redefine ambulatory ECG monitoring, particularly for conditions like atrial fibrillation and other cardiac arrhythmias and QT prolongation monitoring in cardiac safety studies in clinical trials. With the growing burden of cardiovascular diseases globally, this invention aligns with the company’s mission to fight heart disease and improve outcomes through accessible, reliable, and patient-friendly solutions. The company plans to commercialize this breakthrough technology, expanding its presence in key markets, including the U.S., U.K., and Australia, to further strengthen its leadership in the healthcare technology sector.
